Skip to content
Acting Auditions – Lifestyle
Author:
Erasca, Inc.
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 8, 2026
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association’s 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
May 28, 2026
Foundayo and Zepbound now covered for millions of Americans
May 28, 2026
Erasca to Present at the Jefferies Global Healthcare Conference
May 27, 2026
←
Previous Page
1
2
3